Prognostic factors in Guillain-Barre syndrome

Öz

Objective: Guillain–Barre syndrome (GBS) is an immune-mediated disorder of peripheral nerves resulting as acute inflammatory demyelinating polyradiculoneuropathy. GBS has a heterogeneous clinical course and laboratory findings. Acute onset and progressive course, and is usually associated with a good prognosis but some forms have a poor prognosis. Factors that can affect the prognosis of GBS have been investigated in several studies. Assessment of poor prognostic factors of GBS plays a vital role in the management and monitorization of patients. Methods: In this retrospective study of patients admitted to the acute phase of GBS removing clinical and laboratory profiles and was planned to investigate the prognostic factors. Results: Totally 23 patients (Female/male: 16/7) were recruited. Mean age was 47 (range: 17-70) years. Statistically significant poor prognostic factors were advanced age (p=0.042), erythrocyte sedimentation rate (p=0.027) and serum albumin level (p=0.007). Conclusion: Advanced age, increased ESR and decreased albumin levels were found as poor prognostic factors in GBS.

Anahtar Kelimeler

• Guillain-Barre syndrome, advanced age, sedimentation, albumin

Guillain-Barre sendromunda prognostik faktörler

Öz

Amaç: Guillain-Barre Sendromu (GBS), oldukça yaygın görülen otoimmün kökenli, periferik sinirleri etkileyen akut inflamatuar demiyelinizan bir poliradikülopatidir. Oldukça heterojen klinik ve laboratuvar bulgularıyla karşımıza çıkabilir. Ani başlangıçlı, progresif seyirli ve çoğunlukla iyi prognozludur. Ancak bazı formları kötü seyirlidir. GBS\'nin prognozunu etkileyebilen faktörler çeşitli çalışmalarla araştırılmaktadır. Prognostik faktörlerin bilinmesi hastaların tedavi ve izlem planlarında önemli rol oynayabilir. Yöntemler: Bu retrospektif çalışmada akut dönem GBS olarak izlenen hastaların klinik ve laboratuvar profillerinin çıkarılması ve prognostik faktörlerin araştırılması planlandı. Bulgular: Çalışmaya GBS tanısı almış 7 erkek, 16 kadın (toplam 23 hasta) dahil edildi. Yaş ortalamaları 47 yıl (17- 70 arası) idi. İleri yaş (p=0,042), ileri parezi varlığı (p=0,030), sedimantasyon (ESR) (p=0,027) ve serum albümin (p=0,007) düzeyleri prognostik faktörler olarak bulundu. Sonuç: İleri yaş, artmış sedimentasyon hızı, ve azalmış albümin düzeyleri hastalık prognozu üzerine olumsuz etkili olarak bulundu.

Anahtar Kelimeler

• Guillain Barre sendromu, ileri yaş, sedimantasyon, albümin

Kaynakça

1. Inés González-Suárez I, Sanz-Gallego, Rivera FJR, et al. Guillain-Barré Syndrome: Natural history and prognostic factors: a retrospective review of 106 cases. BMC Neurol- ogy 2013;21:13-95.
2. Pişkin İE, Çalık M, Yarımay G, et al. Neck stiffness in Guil- laine-Barre syndrome subsequent to cytomegalovirus in- fection. Dicle Med J 2011;38:104-106.
3. Soysal A, Aysal F, Caliskan B, et al: Clinico-electrophysio- logical findings and prognosis of Guillain-Barré syndrome- 10 years’experience. Acta Neurol Scand 2011,123:181– 186.
4. The Italian Guillain-Barré Study Group: The prognosis and main prognostic indicators of Guillain Barré syndrome. A multicentre prospective study of 297 patients. Brain 1996, 119:2053–2061.
5. Lawn ND, Fletcher DD, Henderson RD, et al. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 2001,58:871–872.
6. Ropper AH, Widjicks EFM, Truax BT (Eds): Guillain- Barré syndrome. Philadelphia: F.A. Davis; 1991.
7. Van Koningsveld R, Steyeberg EW, Hughes RA, et al: A Clinical Prognostic Scoring System For Guillain Barre Syndrome. G Lancet Neurol. 2007 Jul; 6:572-573.
8. De Jager AE, Sluiter HJ: Clinical signs in severe Guillain Barre Syndrome: Analysis of 63 patients. J Neurol Sci 1991;104:143-150.

9. Kuwobara S, Misawa S, Mori M, et al. Long term progno- sis of chronic inflammatory demyelinating polyneuoropa- thy: a five year follow up of 38 cases. J Neurol Neurosurg Psiychiatry 2006;77:66-100.
10. França MC Jr, Deus-Silva L, de Castro R, et al: Guillain– Barre Syndrome in the elderly: Clinical, electrophysiolo- gial, therapeutic and outcome features. Arq Neuropsiquiatr 2005; 63(3B) 772-775.
11. Cheng BC, Chang WN, Chang CS, et al. Guillain Barre Syndrome in Southern Taiwan. Clinical features, prog- nostic factors and therapeutic outcomes. Eur J Neurol 2003;10:655-662.
12. Higara A, Mori M, Ogawara K, et al. Recovery patterns and long term prognosis for axonal Guillain Barre Syndrome: Neurol Neurosurg 2005;76;622.
13. Areeyapinan P, Phanthumchinda K. Guillain-Barre syn- drome: a clinical study in King Chulalongkorn Memorial Hospital. J Med Assoc Thai 2010;93:1150-1155.
14. McKhann GM, Griffin JW, Cornbalth DR, et al. Plasma- pheresis And Guillain Barre Syndrome: analysis of prog- nostic factors and the effect of plasmapheresis. Ann Neurol 1988:23;347-353.
15. Van Doorn PA, Ruts L, Jacobs BC: Clinical features, patho- genesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008,7:939–950.
16. Vucic S, Kiernan MC, Cornblath DR. Guillain-Barré syn- drome: An update. J Cli Neurosci 2009,16:733–741.
17. Endo K, Yasui K, Hasegawa Y, et al. An adult Guillain- Barré syndrome patient with enhancement of anterior roots on spinal MRI and severe radicular pain relieved by intra- venous methylprednisolone pulse therapy: A case report. Rinsho Shinkeigaku. 2013;53:543-550.
18. Tada M, Onodera O, Kawachi I, et al. Steroid-pulse therapy in Guillain-Barré syndrome associated with cytomegalovi- rus infection: a case report. No To Shinkei. 2003;55:615- 621.
19. Aulkemeyer P, Brinkmeier H, Wollinsky KH et al. The human endogenous local anesthetic-like factor (ELLF) is functionally neutralized by serum albumin. Neurosci Lett. 1996;216:37-40.
20. Sanjay R, Flanagan J, Sonado D, et al : The Acute Phase Reactant, Fibrinogen, As A Guide To Plasma Exchange Therapy For Acute Guillain-Barre Syndrome. J Clin Apher 2006; 21:105-110.
21. Tönnessen TI, Nyland H, Aarli JA: Complement factors and acute phase reactants in the Guillain Barre Syndrome. Eur Neurol 1982;21:124-128.
22. Hartung HP, Schwenke C, Bitter-Suermann D, et al. Guil- lain Barre syndrome: Activated complement components C3a and C5a in CSF. Neurology 1987;37:1006.